New drug cocktail shows promise in advanced lung cancer trial

NCT ID NCT05664971

Completed Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS004 (anti-BTLA antibody) combined with toripalimab and standard chemotherapy
What this could lead to: If successful, this combination could offer a new treatment option for advanced lung cancer patients who have limited choices.
What could go wrong: This is an early-phase trial (phase 1/2) focused on safety and dosing, so it is too soon to know if it works. Side effects from the immune-based drugs and chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG CANCER

Contacts and locations

Locations

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.